| Karen Leslie Brinkman, LMFT | |
|
1999 S Bascom Ave Ste 700, Campbell, CA 95008-2205 | |
| (408) 466-5774 | |
| Not Available |
| Full Name | Karen Leslie Brinkman |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 1999 S Bascom Ave Ste 700, Campbell, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043963598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 130048 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Karen Leslie Brinkman, LMFT 1999 S Bascom Ave Ste 700, Campbell, CA 95008-2205 Ph: (408) 466-5774 | Karen Leslie Brinkman, LMFT 1999 S Bascom Ave Ste 700, Campbell, CA 95008-2205 Ph: (408) 466-5774 |
News Archive
Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.
Healthcare group, Stirling Products Limited (ASX:STI) has advised that following the recent TeleMedCare e-health acquisition and the conditional addition of the recently announced pathology business (subject to due diligence completion and shareholder approval), the Company is now in process of its strategised business integration.
Presidio Pharmaceuticals, Inc. announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the initiation of a Phase 1 first-in-human clinical trial of PPI-461, an orally administered NS5A inhibitor for the treatment of hepatitis C virus (HCV). The Phase 1 clinical trial will be conducted in healthy volunteers.
Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.
New research reveals that metabolic syndrome-risk factors that can lead to heart disease and/or stroke-is common in liver transplant recipients, with rates highest at one year following the procedure.
› Verified 8 days ago
Dr. Roger Per-erik Karlsson, PH.D., ABPP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 51 East Campbell Avenue, Ste 170, Campbell, CA 95008 Phone: 510-847-5592 | |
Dr. Colleen Anne Johnson, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 15 Maravilla Ct, Campbell, CA 95008 Phone: 408-781-8434 | |
Dr. Terri Ladonna Thompson, PSY.D. Psychologist Medicare: Medicare Enrolled Practice Location: 900 E Hamilton Ave, Suite 100, Campbell, CA 95008 Phone: 408-802-6391 Fax: 408-879-7205 | |
Dr. Rebecca Caldwell, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2542 S Bascom Ave Ste 100, Campbell, CA 95008 Phone: 800-913-2615 | |
Dr. Christopher Scott Polizzi, PSY.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 901 Campisi Way, Ste 150, Campbell, CA 95008 Phone: 408-827-1942 Fax: 408-628-0042 | |
Dr. David Frederick Dahl, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2542 S Bascom Ave, Ste 265, Campbell, CA 95008 Phone: 408-793-0313 Fax: 408-796-7592 |